vyd222
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Mar 28, 2023 (NCT05791318)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2INHIBITOR
inhibitor - SARS-CoV-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06039449 | Phase 3 | Sep 8, 2023 | Invivyd, Inc. |
| NCT05791318 | Phase 1 | Mar 28, 2023 | Invivyd, Inc., Novotech |
| NCT06004128 | N/A | — | Invivyd, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Invivyd, Inc. | For profit | 3 | 3 | 3 | 2023 |
| Novotech | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1